09.03.2013 Views

Inhibitor SourceBook™ Second Edition

Inhibitor SourceBook™ Second Edition

Inhibitor SourceBook™ Second Edition

SHOW MORE
SHOW LESS

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

Calbiochem • <strong>Inhibitor</strong> SourceBook<br />

Phosphorylation/Dephosphorylation<br />

Protein Kinase G (PKG; cGMP-Dependent Protein Kinase) <strong>Inhibitor</strong>s<br />

cGMP produces its effects by interacting with<br />

intracellular receptor proteins. A primary action of<br />

elevated cGMP levels is the stimulation of cGMPdependent<br />

protein kinase (PKG), which catalyzes the<br />

phosphorylation of a number of physiologically relevant<br />

proteins involved in contractile activity of smooth<br />

muscle cells. The mammalian PKG family consists of<br />

PKGIa and Ib, splice forms derived from one gene, and<br />

PKGII, encoded by a second gene. They are ubiquitous<br />

effector enzymes that regulate a variety of physiological<br />

processes in response to nitric oxide and natriuretic<br />

agonists. Cells of the cardiovascular system, such as<br />

fibroblasts and certain types of endothelial cells, contain<br />

PKGI. Smooth muscle cells are rich in PKGIa and Ib,<br />

platelets and T lymphocytes contain PKGIb, and cardiac<br />

myocytes contain PKGIa. It is important to note that<br />

PKGs are lost in many primary cell types upon passaging<br />

in cell culture and may not be detected in many cell<br />

lines. Studies have shown that cultured vascular smooth<br />

muscle cells (VSMCs) may stop expressing PKG and<br />

acquire a non-contractile phenotype. The restoration<br />

of PKG expression can result in the cells acquiring<br />

a more contractile phenotype. This is an important<br />

observation because several vascular disorders result<br />

from accumulation of noncontractile VSMC in the<br />

vessel wall. In endothelial cells PKGI phosphorylates<br />

and activates eNOS, which reduces its Ca 2+ -dependence.<br />

Also, in endothelial cells, PKGI and PKGII are known<br />

to phosphorylate 6-pyruvoyltetrahydropterin synthase<br />

to produce tetrahydrobiopterin, a required cofactor for<br />

eNOS activation.<br />

References:<br />

Protein Kinase G (PKG; cGMP-Dependent Protein Kinase) <strong>Inhibitor</strong>s<br />

Feil, R., et al. 2005, Rev. Neurosci. 16, 23.<br />

Munzel, T., et al. 2003. Circulation 108, 2 72.<br />

Browning, D.D., et al. 200 . J. Biol. Chem. 276, 3039.<br />

Wang, X., and Robinson, P.J. 997. J. Neurochem. 68, 443.<br />

Lincoln, T.M., et al. 200 . J. Appl. Physiol. 91, 42 .<br />

Product Cat. No. Comments Size Price<br />

A3, Hydrochloride 100122 [N-(2-Aminoethyl)-5-chloronaphthalene-1-sulfonamide, HCl]<br />

A shorter alkyl chain derivative of W-7 (Cat. No. 68 629) that inhibits PKG (K i = 3.8 mM),<br />

casein kinase I (K i = 80 mM), casein kinase II (K i = 5. mM), MLCK (K i = 7.4 mM), PKA<br />

(K i = 4.3 mM), and PKC (K i = 47 mM).<br />

Drosophila<br />

Antennapedia Homeo-<br />

Domain (43-58)<br />

Guanosine 3´,5´-cyclic<br />

Monophosphorothioate,<br />

Rp-Isomer,<br />

Triethylammonium Salt<br />

Guanosine 3´,5´-cyclic<br />

Monophosphorothioate,<br />

8-Bromo-, Rp-Isomer,<br />

Sodium Salt<br />

Guanosine 3´,5´-cyclic<br />

Monophosphorothioate,<br />

8-(4-Choloro-<br />

phenylthio)-, Rp-<br />

Isomer,<br />

Triethylammonium Salt<br />

Guanosine 3´,5´-cyclic<br />

Monophosphorothioate,<br />

b-Phenyl- , N 2 -etheno-<br />

8-bromo-, Rp-Isomer,<br />

Sodium Salt<br />

More online... www.calbiochem.com/inhibitors/PKG<br />

287895 (DT-5; RQIKIWFQNRRMKWKK)<br />

The membrane translocation signal sequence from Drosophila Antennapedia homeodomain<br />

(43-58) that inhibits PKGIa (K i = 970 nM). Does not exhibit significant inhibition<br />

against PKA (K i = 07 mM).<br />

370666 (Rp-cGMPS, TEA)<br />

A competitive inhibitor of PKGIa that blocks PKG and PKA activation (K i = 20 mM).<br />

Exhibits low cell permeability.<br />

370674 (Rp-8-Br-cGMPS, Na)<br />

A potent, cell-permeable, metabolically stable inhibitor of PKG. Significantly more<br />

lipophilic and membrane-permeable than cGMP or Rp-cGMPS. Resistant to mammalian<br />

cyclic nucleotide-dependent phosphodiesterases.<br />

370677 (Rp-8-pCPT-cGMPS, TEA)<br />

A potent, cell-permeable inhibitor of PKG Ia, Ib, and type II. A combination of the protein<br />

kinase inhibitor Rp-cGMPS and the widely used cGMP analog, 8-pCPT-cGMP. Significantly<br />

more lipophilic and membrane-permeant than Rp-cGMPS and Rp-8-Br-cGMPS. Resistant<br />

to hydrolysis by mammalian cyclic nucleotide dependent phosphodiesterases.<br />

370679 (Rp-8-Br-PET-cGMPS, Na)<br />

A metabolically stable, competitive inhibitor of PKGIa and Ib (K i = 30 nM).<br />

Also reported to block the activation of purified PKA type II (K i = 0 mM).<br />

More lipophilic and cell-permeable than Rp-8-pCPT-cGMPS (Cat. No. 370677).<br />

0 mg $90<br />

mg $90<br />

5 mmol $348<br />

5 mmol $430<br />

mmol $2 5<br />

mmol $ 4<br />

Technical Support<br />

Phone 800 628 8470<br />

E-mail calbiochem@emdbiosciences.com<br />

43

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!